Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 7 of 10 for:    Orencia | psoriasis

Abatacept Bone Effects in Psoriatic Arthritis With Bone Biomarker

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04106804
Recruitment Status : Recruiting
First Posted : September 27, 2019
Last Update Posted : September 27, 2019
Sponsor:
Information provided by (Responsible Party):
University of Erlangen-Nürnberg Medical School

Brief Summary:
Observation has pointed out, that osteitis present in the MRI scans, predicts bone erosion and that this in accordance with the concept by underlining the importance of bone marrow involvement in arthritis [Krabben A, 2013]. Abatacept with its favourable safety profile preferentially interrupts activation of naïve T cells and perhaps makes the strongest case for exploiting co-stimulatory blockade during the earliest detectable phase of the adaptive immune response at a time when predisposition to autoimmune disease can be detected.

Condition or disease Intervention/treatment Phase
Evaluate Bone Changes in Patients With PsA Drug: Abatacept 125 MG/ML Phase 4

Detailed Description:
Psoriatic arthritis (PsA) is a chronic inflammatory arthritis that occurs in individuals with psoriasis. It is estimated that 1% to 3% of the general population have psoriasis.1,2,3 In Europe the prevalence of psoriasis ranges up to 6.5%.4 Between 10% and 30% of subjects with Psoriasis develop arthritis. As a result, PsA is the second most common inflammatory arthropathy, following rheumatoid arthritis (RA). 1,2,3 Psoriatic arthritis, a seronegative spondyloarthropathy, is a complex disease involving peripheral and axial joints and periarticular structures resulting in enthesitis and dactylitis. Without appropriate management, the number of joints affected by PsA and the severity of joint damage increase over time, which can lead to marked restriction of daily activities and to substantially compromised quality of life. There is evidence that active PsA is associated with accelerated atherosclerosis, obesity, metabolic syndrome and cardiovascular disease. Other co-morbidities such as pulmonary fibrosis, uveitis, and, less commonly, aortic insufficiency, also contribute to the complexity of PsA.5 Unlike RA, effective treatment options are limited for PsA. Responses to the traditional disease-modifying anti-rheumatic drugs (DMARDs) have been suboptimal.6 There is a significant unmet medical need for more effective and safe therapies in PsA, especially for reducing the arthritic signs and symptoms as well as inhibiting progression of structural damage in joints. About 20% of subjects with PsA will develop a severe destructive disabling form of arthritis.7 In the absence of definitive therapy, more than 50% of subjects with PsA will develop 5 or more deformed joints within 10 years of the onset of disease.8 TNFi therapies are efficacious for both skin and joint diseases and have been shown to inhibit structural damage, but approximately 40% of subjects treated with TNFi agents do not reach a minimal improvement [American College of Rheumatology [ACR) 20]9,10,11,12.13,14,15,16,17 In addition, serious adverse events (SAEs) including infections and injection site reactions have been associated with the use of TNFi therapies. Although in some studies a small percentage of patients previously exposed to TNFi were included, these studies were not powered to demonstrate efficacy in that sub-population. Thus, in subjects who experience inefficacy or intolerance of TNF blockade, there is still medical need for new options. Therefore, there is still need in PsA for therapies that provide significant improvement in arthritis and a risk benefit profile that is acceptable. Therapies directed at novel targets (IL-12/23, PDE4-Antagonist) are also approved since 2014. 18, 19, 20, 21 Joint involvement, is clearly the most prominent example for the systemic nature of psoriasis. Notably, the burden of joint disease in patients with psoriasis may be even higher, given that not all psoriasis patients experiencing musculoskeletal complaints fulfill the classification criteria of PsA22. If present, PsA is a severe disease associated with impaired function and reduced life quality life.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Intervention Model Description: The study is a single arm interventional study with a treatment phase of 6 months.
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Abatacept Bone Effects in Psoriatic Arthritis With Bone Biomarkers - ABEPSA _ BB
Actual Study Start Date : June 6, 2018
Estimated Primary Completion Date : August 2021
Estimated Study Completion Date : August 2022

Resource links provided by the National Library of Medicine

Drug Information available for: Abatacept


Intervention Details:
  • Drug: Abatacept 125 MG/ML
    Patients will receive weekly abatacept (Orencia®) s.c. Abatacept in the dose regimen given in the label for RA and PsA for six months


Primary Outcome Measures :
  1. Bone Erosion volume [ Time Frame: 6 months ]
    Change in bone erosion volume measured by Hr-PQ CT of the involved hand between baseline and 24 weeks follow-up


Secondary Outcome Measures :
  1. Comparing bone Erosion baseline to week 24 [ Time Frame: 6 months ]
    Change in bone erosion on CT between baseline and 24 wks

  2. Comparing Osteophytes between baseline and week 24 [ Time Frame: 3 and 6 months ]
    Change in osteophytes CT between baseline and 24 wks

  3. Comparing Tenosynovitis between baseline, month 3 and month 6 [ Time Frame: 3 and 6 months ]
    Change in MRI Tenosynovitis score between baseline compared to month 3 and 6

  4. Comparing PSAMRIS score between baseline and month 3 and month 6 [ Time Frame: 3 and 6 months ]
    Change in PSAMRIS MRI score between baseline compared to month 3 and 6

  5. Comparing bone Erosion between baseline month 3 and and month 6 with MRI [ Time Frame: 3 and 6 months ]
    Change in MRI bone erosions between baseline compared to month 3 and month 6

  6. Comparing Synovitis between baseline and month 3 and month 6 [ Time Frame: 3 and 6 months ]
    Change in MRI synovitis between baseline compared to month 3 and month 6

  7. Comparing DAS28 from baseline to month 3 and month 6 [ Time Frame: 3 and 6 months ]
    Change of DAS28 between baseline compared to month 3 and month 6

  8. Comparing DAPSA between baseline, month 3 and month 6 [ Time Frame: 3 and 6 months ]
    Change of DAPSA between baseline compared to month 3 and month 6

  9. Comparing MDA from baseline, month 3 and month 6 [ Time Frame: 3 and 6 months ]
    Change of MDA between baseline compared to month 3 and month 6

  10. Comparing HAQ-DI between baseline compared to month 3 and month 6 [ Time Frame: 3 and 6 months ]
    Change of HAQ-DI between baseline compared to month 3 and month 6

  11. Comparing SPARCC between baseline compared to month 3 and month 6 [ Time Frame: 3 and 6 months ]
    Change of SPARCC between baseline compared to month 3 and month 6

  12. Comparing PSAID between baseline compared to month 3 and month 6 [ Time Frame: 3 and 6 months ]
    Change of PSAID between baseline compared to month 3 and month 6

  13. Comparing PASI between baseline compared to month 3 and month 6 [ Time Frame: 3 and 6 months ]
    Change of PASI between baseline compared to month 3 and month 6

  14. Comparing SF36 between screening, month 3 and month 6 [ Time Frame: 3 and 6 months ]
    Change of SF36 between screening, month 3 and month 6



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Males/females with CASPAR criteria-positive PsA
  • Active disease with more than three swollen and tender joints
  • Must be aged ≥ 18 years at time of consent
  • ≥ 3 erosions on MRI or HR PQCT
  • Women of childbearing potential or men capable of fathering children must be using effective contraception during treatment with abatacept and up to 14 weeks after the last dose of abatacept treatment.
  • Must understand and voluntarily sign an informed consent form including written consent for data protection ´- Must be able to adhere to the study visit schedule and other protocol requirements

Exclusion Criteria:

  • Previous exposure to abatacept
  • CCP2 positivity
  • Investigational study drug within 4 weeks (or 5 halflives (half live is 14,3 days), whichever is longer) prior to randomisation
  • Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study
  • Any other autoimmune or inflammatory disease such as SLE, PSS, MCTD, SpA, Behcet disease, vasculitis or autoimmune hepatitis.
  • Any malignancy in the last 5 years
  • Chronic infection such as latent TB (TB not adequately treated according to guidelines) or hepatitis B or C infection
  • Immunocompromised or HIV-positive patients
  • Uncontrolled severe concomitant disease
  • Patients who are younger than 18 years or are incapable to understand the aim, importance and consequences of the study and to give legal informed consent (according to § 40 Abs. 4 and § 41 Abs. 2 and Abs. 3 AMG).
  • Pregnant or lactating females
  • Patients who possibly are dependent on the Principal Investigator or

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04106804


Contacts
Layout table for location contacts
Contact: Juergen Rech, MD +49-91318543014 juergen.rech@uk-erlangen.de

Locations
Layout table for location information
Germany
University Clinic Erlangen, Medical Department 3, Rheumatology & Immunology Recruiting
Erlangen, Germany, 91054
Contact: Dagmar Werner    +49-91318532093    dagmar.werner@uk-erlangen.de   
Sponsors and Collaborators
University of Erlangen-Nürnberg Medical School

Layout table for additonal information
Responsible Party: University of Erlangen-Nürnberg Medical School
ClinicalTrials.gov Identifier: NCT04106804     History of Changes
Other Study ID Numbers: ABEPSA_BB
First Posted: September 27, 2019    Key Record Dates
Last Update Posted: September 27, 2019
Last Verified: September 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by University of Erlangen-Nürnberg Medical School:
Psoriatic arthritis; Bone
Additional relevant MeSH terms:
Layout table for MeSH terms
Psoriasis
Abatacept
Arthritis
Arthritis, Psoriatic
Joint Diseases
Musculoskeletal Diseases
Spondylarthropathies
Spondylarthritis
Spondylitis
Spinal Diseases
Bone Diseases
Skin Diseases, Papulosquamous
Skin Diseases
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents